Lars M. Wagner, MD
Pediatric Hematology-Oncology Specialist
Schedule Online
My Locations
About Me
The field of pediatric oncology offers a tremendous opportunity to improve the lives of cancer patients through the discovery, development, and compassionate administration of treatment. It is a privilege to journey alongside these patients and their families, and I learn from them each day. It is also a privilege to work with a dedicated and talented team of physicians and other medical staff as we try to comprehensively address the needs of our patients. Although I see a variety of children with cancer or blood diseases, my research focus is in sarcoma, which are tumors of connective tissue such as bone or muscle. Collaboration is necessary for progress, and my goal is to work with other clinicians and researchers at Duke Health and across the country to provide the very best treatment and support for the patients who have been entrusted to our care.
- Professor of Pediatrics, Pediatrics, Hematology-Oncology 2021
- Chief, Division of Hematology/Oncology, Pediatrics, Hematology-Oncology 2018
- Member of the Duke Cancer Institute, Duke Cancer Institute 2018
Call for an Appointment
Ratings and Reviews
The ratings and reviews are based on patient responses to the overall provider rating question from the survey. The question reads: “Using any number from 0 to 10, where 0 is the worst provider possible and 10 is the best provider possible, what number would you use to rate this provider?” Responses are converted to a 5-point rating system and applied consistently to all providers. Learn more about our survey process. Patients who see some types of providers receive a different version of the patient satisfaction survey. Those results are not available on DukeHealth.org.
Training and Education
Clinical Focus and Research
My research focus is on the development of new therapies for pediatric and young adult patients with sarcoma. I work with other clinicians across the country to develop new treatment regimens for sarcoma patients to better understand the nature of sarcoma and how patients respond to treatment. It is only through clinical trials that we can further our understanding of this rare disease and hopefully continue to improve the outcome of our patients.
- Dhir, Aditi, Masanori Hayashi, Avery Bodlak, Javier Oesterheld, David M. Loeb, Leo Mascarenhas, Michael S. Isakoff, et al. “Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation.” Clin Cancer Res 30, no. 23 (December 2, 2024): 5314–22. https://doi.org/10.1158/1078-0432.CCR-24-1339.
- Zachman, Derek K., Jonathan G. Bardahl, Laurie A. Graves, and Lars M. Wagner. “Impact of Duffy-associated neutrophil count on maintenance chemotherapy management in a child with acute lymphoblastic leukemia.” Pediatr Blood Cancer 71, no. 12 (December 2024): e31355. https://doi.org/10.1002/pbc.31355.
- Leraas, Harold, Mary Moya-Mendez, Victoria Donohue, Brad Kawano, Lindsay Olson, Akshaya Sekar, Joanna Robles, et al. “Using Crowdfunding Campaigns to Examine Financial Toxicity and Logistical Burdens Facing Families of Children With Wilms Tumor.” J Surg Res 291 (November 2023): 640–45. https://doi.org/10.1016/j.jss.2023.07.005.
- Basin, Alice, Brandon Howard, Lars Wagner, and Laura Page. “Management of metastatic papillary thyroid carcinoma in a child with ataxiatelangiectasia.” In HORMONE RESEARCH IN PAEDIATRICS, 96:345–46, 2023.
- Dorfman, Caroline S., Juliann Stalls, Rebecca Shelby, Sarah Arthur, Coleman Mills, Jacklyn Balliot, David Van Mater, Lars Wagner, and Cheyenne Corbett. “SEXUAL FUNCTION & SATISFACTION AMONG AYAS WITH CANCER: AN EXAMINATION OF THE ROLE OF AGE, SEX ASSIGNED AT BIRTH, AND PARTNER STATUS.” In ANNALS OF BEHAVIORAL MEDICINE, 57:S444–S444, 2023.
- Zachman, Derek, Laurie Graves, Chelse Sanborn, Sarah Sullivan, Susan Kreissman, Jennifer Rothman, and Lars Wagner. “USE OF A RAPID HYDRATION PROTOCOL FOR PEDIATRIC ONCOLOGY PATIENTS RECEIVING NEPHROTOXIC CHEMOTHERAPY.” In PEDIATRIC BLOOD & CANCER, Vol. 69, 2022.
Insurance Accepted
Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below.
-
Aetna
- Aetna Choice POS, Aetna Choice POS II
- Aetna Elect Choice HMO, Aetna Open Access Elect Choice
- Aetna Health Network Only, Aetna Health Network Option
- Aetna HMO
- Aetna Limited Benefit Insurance PPO
- Aetna Managed Choice POS
- Aetna Medicare Assure Plan (HMO D-SNP)
- Aetna Medicare Eagle Plan (PPO)
- Aetna Medicare Essential Plan (PPO)
- Aetna Medicare Value Plan (HMO)
- Aetna Open Access HMO, Open Access Aetna Select, Aetna Open Access Managed Choice
- Aetna Open Choice PPO
- Aetna PCP Coordinated POS Plan
- Aetna Quality Point of Service (QPOS)
- Aetna Select HMO
- Aetna Traditional Choice
- Aetna Voluntary Indemnity Group Plan
- Aetna Whole Health – Duke WakeMed WKCC
- Aetna/CVS Health
-
Ambetter
- Ambetter of North Carolina
-
Blue Cross Blue Shield of NC
- Blue Advantage
- Blue Medicare (HMO, PPO)*
- Blue Options (123, PPO, HSA)
- Blue Select
- NC State Employees Health Plan
-
*Duke HomeCare and Hospice does not participate in the plan.
-
Cigna
- Cigna Behavioral Health (*Limited eligibility)
- Cigna Choice Plus
- Cigna Connect Individual Family Plan
- Cigna Open Access
- Cigna Open Access Plus
-
*Please call Cigna Behavioral Heath to see if the provider is participating in your plan.
-
Duke Group Plans
- Duke Basic
- Duke Select
-
Experience Health
- Experience Health Medicare Advantage (HMO) Plan
- Gateway Health Alliance
- Healthgram
-
Humana
- Humana Choice (PPO)
- Humana Choice - Medicare Advantage (PPO)
- Humana ChoiceCare - Medicare Advantage (PPO)
- Humana Gold Choice - Medicare Advantage (PFFS)
- Humana Gold Plus - Medicare Advantage (HMO)
- Humana Medicare Advantage Group Plan - NC State Retirees
- MedCost
-
Medicare
- First Medicare Direct
- Medicare Part A
- Medicare Part B
-
NC Medicaid
- AmeriHealth Caritas North Carolina
- Carolina Complete Health
- Healthy Blue
- NC Medicaid Direct
- WellCare of North Carolina
-
TRICARE
- TRICARE Prime
- TRICARE Prime Remote
- TRICARE Select
-
United Healthcare
- AARP Medicare Advantage Plan 2 (HMO-POS)
- AARP Medicare Complete (HMO, PPO)*
- AARP Medicare Complete Essential (HMO)*
- All Savers Alternate Funding
- All Savers Fully Insured
- United Healthcare (HMO, PPO, POS)**
- United Healthcare Charter/Charter Balance/Charter Plus
- United Healthcare Choice/Choice Plus
- United Healthcare Core/Core Essential
- United Healthcare Navigate/Navigate Plus/Navigate Balanced
- United Healthcare Option PPO
- United Healthcare Passport Connect Choice/Choice Plus
- United Healthcare Passport Connect Options PPO
- United Healthcare Select/Select Plus
- United Healthcare Shared Services - Harvard Pilgrim/UHC Options PPO Network
- United Medical Resources (UMR)
-
*Duke HomeCare and Hospice and mental health providers do not participate with the plan.
-
**Duke Health does not participate in UHC plans on the Health Insurance Marketplace.
Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy.
External Relationships
- Jazz Pharmaceuticals